While CIML natural killer immunotherapy can result in infection-like reactions, required prior chemo may cause infections, ...

Panelists discuss updated MonumenTAL-1 trial data demonstrating high response rates and prolonged survival with ...

Panelists discuss updated safety findings from GPRC5D-targeted bispecific therapy in relapsed/refractory multiple myeloma, ...

Patients receiving subcutaneous daratumumab have less chair time and premedication than those receiving IV formulation, says ...

Panelists discuss how patients newly diagnosed with multiple myeloma often face emotional and informational overload, but ...

Panelists discuss how patient portal use improves communication by allowing patients to report adverse effects with photos ...

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the ...

Panelists discuss the evolving role of bispecific antibodies in relapsed/refractory multiple myeloma, emphasizing their value ...

Most patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell ...

A quality-adjusted time without symptoms or toxicity analysis identified better outcomes for patients with RCC treated with belzutifan vs everolimus.

Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.

If patients with breast cancer have hyperglycemia or symptoms of it at home, a short break from capivasertib may be required, ...